ChemBridge Research Laboratories, Inc. (CRL) has Established an Industry Record and Benchmark in Hit-to-Lead Libraries Turn-around Time
SAN DIEGO, August 7 /PRNewswire/ --
ChemBridge Research Laboratories, Inc. (CRL) announced today that it has
established an industry record in turn-around time for hit-to-lead follow-up
libraries. Such ultra-fast hit-to-lead libraries are now produced in CRL's
San Diego facilities in a matter of three to six days which enables critical
acceleration of our clients' medicinal chemistry projects and sets a new
industry benchmark. This state-of-the-art high-throughput chemistry
technology was developed at CRL over the last seven years and refined in
collaborations with Pfizer, Merck, AstraZeneca and others.
CRL's ultra-fast library production process is optimized at every step
and includes: on-the-fly building block validation and protocol adjustment;
one to three parallel synthesis steps across a very broad reaction range;
high-throughput HPLC purification and LC/MS analysis; data processing;
and robotic reformatting to ready-to-be-shipped custom plates/vials. The
expertise, problem solving ability, and versatility of synthetic skills of
CRL's chemists (the majority of whom are PhD's) also allow for rapid
development of new parallel synthetic protocols and multi-step synthesis of
intermediates and templates on-the-fly for the most challenging
research-intensive hit-to-lead libraries.
"We are very pleased that our CRL chemists have been able to achieve
speed and efficiency in hit-to-lead library production which even a year ago
was not considered possible," said Eugene Vaisberg, Chairman and CEO of
ChemBridge Corporation and CRL. "Their ability to produce and deliver high
Quality hit-to-lead libraries in less than a week continues the ChemBridge
tradition of setting a gold standard in discovery chemistry outsourcing. It
also offers a substantial competitive advantage for our clients allowing
their precious medicinal chemistry resources to focus on their core expertise
and to improve their hit-to-drug candidate success rate and timelines. This
is of foremost importance now when research efficiency and productivity
becomes the 'name of the game' for the pharmaceutical and biotech industry."
About ChemBridge Research Laboratories, Inc. (CRL)
ChemBridge Research Laboratories, Inc. (CRL),
http://www.chembridgeresearch.com, is a San Diego based discovery chemistry
CRO, which provides chemistry solutions for early stages of small molecule
drug discovery. Founded in 2000 as a spin-off of ChemBridge Corporation, CRL
has now become a center of excellence in high-throughput medicinal chemistry
with a particular focus on ultra-fast hit-to-lead libraries. CRL's
world-class research team has exceeded expectations in all its
collaborations, including multi-year alliances with Pfizer, Merck,
AstraZeneca and other major pharmaceutical and biotech companies.
About ChemBridge Corporation
ChemBridge Corporation, http://www.chembridge.com, is a leading global
discovery chemistry CRO and screening compound library provider with an
impeccable 15 year track record of quality and deliverability. ChemBridge is
a San Diego based company which operates a state-of-the-art offshore
discovery chemistry research site in Moscow, Russia. ChemBridge's CRO
business includes multi-year strategic alliances with major pharmaceutical
companies such as Pfizer, Merck, and AstraZeneca, as well as smaller research
collaborations with mid-size pharmaceutical and biotech companies. Over 500
pharmaceutical and biotech companies and universities worldwide have also
taken advantage of ChemBridge's portfolio of advanced discovery chemistry
off-the-self products, including its library of 700,000 diverse drug-like
small molecule screening compounds and 10,000 building blocks.
Web site: http://www.chembridge.com
Julia Pustilnik, Director, Alliance Management of ChemBridge Corporation and CRL, +1-858-451-7400, ext. 170, ultrafast-libraries@chembridge.com